Pall Life Sciences has entered a long-term agreement with the New York Blood Center (NYBC) to support the organisation's transition to a new filtration system that improves efficiency when removing white blood cells from donated blood.
www.pall.com
New York, New York
“The New York Blood Center’s commitment to this technology will ensure that it can continue to provide the region’s hospitals with the blood needed to meet increasingly stringent requirements,” said Robert L Jones, NYBC president and CEO. “In-line filtration will help us advance the safe and effective collection of blood while improving plasma yields and increasing platelet availability.”
www.pall.com